Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: Results from the ovarian cancer association consortium pooled analysis

British Journal of Cancer

Volumn 98, Issue 2, 2008, Pages 282-288

  Pearce, C L ^a   Wu, A H ^a   Gayther, S A ^b   Bale, A E ^c   Beck, P A ^c   Beesley, J ^d   Chanock, S ^e   Cramer, D W ^f   DiCioccio, R ^g   Edwards, R ^h   Fredericksen, Z S ⁱ   Garcia Closas, M ^e   Goode, E L ⁱ   Green, A C ^d   Hartmann, L C ⁱ   Hogdall, E ^j   Kjaer S K ^j   Lissowska, J ^k   McGuire, V ^l   Modugno, F ^m   Moysich, K ^g   Ness, R B ^m   Ramus, S J ^b   Risch, H A ^c   Sellers, T A ⁿ   Song, H ^o   Stram, D O ^a   Terry, K L ^f   Webb, P M ^d   Whiteman, D C ^d   Whittemore, A S ^l   Zheng, W ^p   Pharoah, P D P ^o   Chenevix Trench, G ^d   Pike, M C ^a   Schildkraut, J ^q   Berchuck, A ^q   more..

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^e NATIONAL CANCER INSTITUTE   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

^h UNIVERSITY OF PITTSBURGH   (United States)

ⁱ Mayo Clinic   (United States)

^j Rigshospitalet   (Denmark)

^k INSTITUTE OF ONCOLOGY   (Poland)

^l STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

ⁿ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^o UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^p UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^q DUKE CANCER INSTITUTE   (United States)

more..

Author keywords

Endometrioid ovarian cancer; Ovarian cancer; Pooled analyses; Progesterone receptor; PROGINS; SNPs

Indexed keywords

PROGESTERONE; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INVASION; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE LOCUS; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; CARCINOMA, ENDOMETRIOID; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 38549127886     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604170     Document Type: Article

References (44)

1. Agoulnik IU, Tong XW, Fischer DC, Korner K, Atkinson NE, Edwards DP, Headon DR, Weigel NL, Kieback DG (2004) A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. J Clin Endocrinol Metab 89: 6340-6347
2. Akahira J, Inoue T, Suzuki T, Ito K, Konno R, Sato S, Moriya T, Okamura K, Yajima A, Sasano H (2000) Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies. Br J Cancer 83: 1488-1494
3. Auranen A, Song H, Waterfall C, Dicioccio RA, Kuschel B, Kjaer SK, Hogdall E, Hogdall C, Stratton J, Whittemore AS, Easton DF, Ponder BA, Novik KL, Dunning AM, Gayther S, Pharoah PD (2005) Polymorphisms in DNA repair genes and epithelial ovarian cancer risk. Int J Cancer 117: 611-618
4. Berchuck A, Schildkraut JM, Wenham RM, Calingaert B, Ali S, Henriott A, Halabi S, Rodriguez GC, Gertig D, Purdie DM, Kelemen L, Spurdle AB, Marks J, Chenevix-Trench G (2004) Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. Cancer Epidemiol Biomarkers Prev 13: 2141-2147
5. Cooper GS, Schildkraut JM, Whittemore AS, Marchbanks PA (1999) Pregnancy recency and risk of ovarian cancer. Cancer Causes Control 10: 397-402
6. De Vivo I, Huggins GS, Hankinson SE, Lescault PJ, Boezen M, Colditz GA, Hunter DJ (2002) A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci USA 99: 12263-12268
7. García-Closas M, Brinton LA, Lissowska J, Sherman ME, Szeszenia-Dabrowska N, Peplonska B, Welch R, Yeager M, Bardin-Mikolajczak A, Zatonski W, Chanock SJ (2007) Ovarian cancer risk and common variation in the sex hormone-binding globulin gene: a population-based case-control study. BMC Cancer 7: 60
8. Gayther SA, Song H, Ramus SJ, Kjaer SK, Whittemore AS, Quaye L, Tyrer J, Shadforth D, Hogdall E, Hogdall C, Blaeker J, DiCioccio R, McGuire V, Webb PM, Beesley J, Green AC, Whiteman DC, Australian Ovarian Cancer Study Group, Goodman MT, Lurie G, Carney ME, Modugno F, Ness RB, Edwards RP, Moysich KB, Goode EL, Couch FJ, Cunningham JM, Sellers TA, Wu AH, Pike MC, Iversen ES, Marks JR, Garcia-Closas M, Brinton L, Lissowska J, Peplonska B, Easton DF, Jacobs I, Ponder BA, Schildkraut J, Pearce CL, Chenevix-Trench G, Berchuck A, Pharoah PDP, Ovarian Cancer Association Consortium (2007) Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res 67: 3027-3035
9. Gemignani ML, Schlaerth AC, Bogomolniy F, Barakat RR, Lin O, Soslow R, Venkatraman E, Boyd J (2003) Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 90: 378-381
10. Hartge P, Schiffman MH, Hoover R, McGowan L, Lesher L, Norris HJ (1989) A case-control study of epithelial ovarian cancer. Am J Obstet Gynecol 161: 10-16
11. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9: 1603-1614
12. Lancaster JM, Berchuck A, Carney ME, Wiseman R, Taylor JA (1998) Progesterone receptor gene polymorphism and risk for breast and ovarian cancer. Br J Cancer 78: 277
13. Lancaster JM, Wenham RM, Halabi S, Calingaert B, Marks JR, Moorman PG, Bentley RC, Berchuck A, Schildkraut JM (2003) No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina. Cancer Epidemiol Biomarkers Prev 12: 226-227
14. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN (2003) Metaanalysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 33: 177-182
15. Manolitsas TP, Englefield P, Eccles DM, Campbell IG (1997) No association of a 306-bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer. Br J Cancer 75: 1398-1399
16. Merritt MA, Green AC, Nagle CM, Webb PM, Australian Cancer Study (Ovarian Cancer), Australian Ovarian Cancer Study Group (2008) Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122: 170-176
17. McKenna NJ, Kieback DG, Carney DN, Fanning M, McLinden J, Headon DR (1995) A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma. Br J Cancer 71: 451-455
18. Ness RB, Grisso JA, Klapper J, Schlesselman JJ, Silberzweig S, Vergona R, Morgan M, Wheeler JE (2000) Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE study group. Steroid Hormones and reproductions. Am J Epidemiol 152: 233-241
19. Norman AW, Litwack G (1997) Estrogens and progestins. In Hormones Norman AW, Litwack G (eds), pp 361-386. San Diego, CA: Academic Press
20. Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G, Thomas EJ, Campbell IG (1998) Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58: 2095-2097
21. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, LaPolla J, Hoffman M, Martino MA, Wakeley K, Wilbanks G, Nicosia S, Cantor A, Sutphen R (2005) BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104: 2807-2816
22. Pearce CL, Hirschhorn JN, Wu AH, Burtt NP, Stram DO, Young S, Kolonel LN, Henderson BE, Altshuler D, Pike MC (2005) Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis. J Natl Cancer Inst 97: 51-59
23. Pike MC, Pearce CL, Peters R, Cozen W, Wan P, Wu AH (2004) Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertil Steril 82: 186-195
24. Risch HA (1998) Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90: 1774-1786
25. Risch HA, Bale AE, Beck PA, Zheng W (2006) PGR +331 A/G and increased risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 15: 1738-1741
26. Rodriguez GC, Walmer DK, Cline M, Krigman H, Lessey BA, Whitaker RS, Dodge R, Hughes CL (1998) Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 5: 271-276
27. Romano A, Delvoux B, Fischer DC, Groothuis P (2007) The PROGINS polymorphism of the human progesterone receptor diminishes the response to progesterone. J Mol Endocrinol 38: 331-350
28. Romano A, Lindsey PJ, Fischer DC, Delvoux B, Paulussen AD, Janssen RG, Kieback DG (2006) Two functionally relevant polymorphisms in the human progesterone receptor gene (+331 G/A and progins) and the predisposition for breast and/or ovarian cancer. Gynecol Oncol 101: 287-295
29. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Lewis Jr JL, Strom BL, Harlap S, Shapiro S (1994) A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 139: 654-661
30. Rosenblatt KA, Thomas DB, Noonan EA (1992) High-dose and low-dose combined oral contraceptives: protection against epithelial ovarian cancer and the length of the protective effect. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Eur J Cancer 28A: 1872-1876
31. Rowe SM, Coughlan SJ, McKenna NJ, Garrett E, Kieback DG, Carney DN, Headon DR (1995) Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion. Cancer Res 55: 2743-2745
32. Royar J, Becher H, Chang-Claude J (2001) Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer 95: 370-374
33. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC (2002) Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 94: 32-38
34. Sellers TA, Schildkraut JM, Pankratz VS, Vierkant RA, Fredericksen ZS, Olson JE, Cunningham J, Taylor W, Liebow M, McPherson C, Hartmann LC, Pal T, Adjei AA (2005) Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. Cancer Epidemiol Biomarkers Prev 14: 2536-2543
35. Song H, Ramus SJ, Quaye L, DiCioccio RA, Tyrer J, Lomas E, Shadforth D, Hogdall E, Hogdall C, McGuire V, Whittemore AS, Easton DF, Ponder BA, Kjaer SK, Pharoah PD, Gayther SA (2006) Common variants in mismatch repair genes and risk of invasive ovarian cancer. Carcinogenesis 27: 2235-2242
36. Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G (2001) No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer. Carcinogenesis 22: 717-721
37. Study C (1987) The reduction in risk of ovarian cancer associated with oral-contraceptive use. The cancer and steroid hormone study of the centers for disease control and the national institute of child health and human development. N Engl J Med 316: 650-655
38. Terry KL, De Vivo I, Titus-Ernstoff L, Sluss PM, Cramer DW (2005) Genetic variation in the progesterone receptor gene and ovarian cancer risk. Am J Epidemiol 161: 442-451
39. Titus-Ernstoff L, Perez K, Cramer DW, Harlow BL, Baron JA, Greenberg ER (2001) Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer 84: 714-721
40. Tong D, Fabjani G, Heinze G, Obermair A, Leodolter S, Zeillinger R (2001) Analysis of the human progesterone receptor gene polymorphism progins in Austrian ovarian carcinoma patients. Int J Cancer 95: 394-397
41. Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP (1993) Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 7: 1244-1255
42. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96: 434-442
43. Whiteman DC, Siskind V, Purdie DM, Green AC (2003) Timing of pregnancy and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 12: 42-46
44. Zhou H, Luo MP, Schonthal AH, Pike MC, Stallcup MR, Blumenthal M, Zheng W, Dubeau L (2002) Effect of reproductive hormones on ovarian epithelial tumors: I. Effect on cell cycle activity. Cancer Biol Ther 1: 300-306